Local delivery of paclitaxel in the treatment of peripheral arterial disease

European Journal of Clinical Investigation

Volumn 45, Issue 3, 2015, Pages 333-345

  Ng, Vivian G ^a   Mena, Carlos ^a   Pietras, Cody ^a   Lansky, Alexandra J ^a  

^a YALE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angioplasty; Drug eluting stent; Peripheral artery disease

Indexed keywords

ALBUMIN; ALBUMIN NANOPARTICLE; IOPROMIDE; NANOPARTICLE; PACLITAXEL; TUBULIN; UNCLASSIFIED DRUG; WATER; CREMOPHOR; DRUG VEHICLE; GLYCEROL; IOHEXOL; TUBULIN MODULATOR;

ANTIPROLIFERATIVE ACTIVITY; ARTERY OCCLUSION; BALLOON; DRUG COATED BALLOON; DRUG DELIVERY DEVICE; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; LEUKOCYTE; LIPOPHILICITY; LOCAL THERAPY; MELTING POINT; MICROTUBULE ASSEMBLY; MIGRATION INHIBITION; MITOSIS; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN STABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); DRUG ELUTING STENT; INTRAVENOUS DRUG ADMINISTRATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ARTERIAL DISEASE; PRECLINICAL STUDY; PROCEDURES;

ANGIOPLASTY, BALLOON; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG-ELUTING STENTS; GLYCEROL; HUMANS; INFUSIONS, INTRAVENOUS; IOHEXOL; NANOPARTICLES; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; PHARMACEUTICAL VEHICLES; TUBULIN MODULATORS;

EID: 84923448799     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12407     Document Type: Review

References (118)

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;45(Suppl S):S5-67.
2. Krepel VM, van Andel GJ, van Erp WF, Breslau PJ. Percutaneous transluminal angioplasty of the femoropopliteal artery: initial and long-term results. Radiology 1985;156:325-8.
3. Gupta AK, Ravimandalam K, Rao VR, Joseph S, Unni M, Rao AS et al. Total occlusion of iliac arteries: results of balloon angioplasty. Cardiovasc Intervent Radiol 1993;16:165-77.
4. Johnston KW. Iliac arteries: reanalysis of results of balloon angioplasty. Radiology 1993;186:207-12.
5. Stokes KR, Strunk HM, Campbell DR, Gibbons GW, Wheeler HG, Clouse ME. Five-year results of iliac and femoropopliteal angioplasty in diabetic patients. Radiology 1990;174:977-82.
6. Tegtmeyer CJ, Hartwell GD, Selby JB, Robertson R Jr, Kron IL, Tribble CG. Results and complications of angioplasty in aortoiliac disease. Circulation 1991;83:I53-60.
7. Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik K et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol 2001;12:23-31.
8. Karch LA, Mattos MA, Henretta JP, McLafferty RB, Ramsey DE, Hodgson KJ. Clinical failure after percutaneous transluminal angioplasty of the superficial femoral and popliteal arteries. J Vasc Surg 2000;31:880-7.
9. Matsi PJ, Manninen HI, Vanninen RL, Suhonen MT, Oksala I, Laakso M et al. Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1-3-year follow-up. Radiology 1994;191:727-33.
10. Soder HK, Manninen HI, Rasanen HT, Kaukanen E, Jaakkola P, Matsi PJ. Failure of prolonged dilation to improve long-term patency of femoropopliteal artery angioplasty: results of a prospective trial. J Vasc Interv Radiol 2002;13:361-9.
11. Soder HK, Manninen HI, Jaakkola P, Matsi PJ, Rasanen HT, Kaukanen E et al. Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: angiographic and clinical results. J Vasc Interv Radiol 2000;11:1021-31.
12. Lammer J, Dake MD, Bleyn J, Katzen BT, Cejna M, Piquet P et al. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. International Trial Study Group. Radiology 2000;217:95-104.
13. Henry M, Amor M, Ethevenot G, Henry I, Amicabile C, Beron R et al. Palmaz stent placement in iliac and femoropopliteal arteries: primary and secondary patency in 310 patients with 2-4-year follow-up. Radiology 1995;197:167-74.
14. Strecker EP, Boos IB, Gottmann D. Femoropopliteal artery stent placement: evaluation of long-term success. Radiology 1997;205:375-83.
15. White GH, Liew SC, Waugh RC, Stephen MS, Harris JP, Kidd J et al. Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anticoagulation. J Vasc Surg 1995;21:270-9; discussion 279-281.
16. Gray BH, Sullivan TM, Childs MB, Young JR, Olin JW. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg 1997;25:74-83.
17. Becquemin JP, Favre JP, Marzelle J, Nemoz C, Corsin C, Leizorovicz A. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg 2003;37:487-94.
18. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study. Cardiovasc Intervent Radiol 1997;20:420-5.
19. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011;4:495-504.
20. Acin F, de Haro J, Bleda S, Varela C, Esparza L. Primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis of randomized controlled trials. J Endovasc Ther 2012;19:585-95.
21. Katsanos K, Spiliopoulos S, Diamantopoulos A, Karnabatidis D, Sabharwal T, Siablis D. Systematic review of infrapopliteal drug-eluting stents: a meta-analysis of randomized controlled trials. Cardiovasc Intervent Radiol 2013;36:645-58.
22. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93.
23. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5.
24. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
25. Scheinert D, Katsanos K, Zeller T, Koppensteiner R, Commeau P, Bosiers M et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol 2012;60:2290-5.
26. Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg 2011;54:394-401.
27. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006;13:701-10.
28. Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 2011;18:613-23.
29. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013;61:2417-27.
30. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
31. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
32. Ellis SG, Colombo A, Grube E, Popma J, Koglin J, Dawkins KD et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3, 445 patients followed for up to 3 years. J Am Coll Cardiol 2007;49:1043-51.
33. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91.
34. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-92.
35. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-11.
36. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
37. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-7.
38. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002;106:2649-51.
39. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006;113:e463-654.
40. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
41. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77:1561-5.
42. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91:479-87.
43. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol 1982;94:688-96.
44. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry 1981;20:3247-52.
45. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981;256:10435-41.
46. Wilson L, Miller HP, Farrell KW, Snyder KB, Thompson WC, Purich DL. Taxol stabilization of microtubules in vitro: dynamics of tubulin addition and loss at opposite microtubule ends. Biochemistry 1985;24:5254-62.
47. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993;90:9552-6.
48. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
49. Wiskirchen J, Schober W, Schart N, Kehlbach R, Wersebe A, Tepe G et al. The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study. Invest Radiol 2004;39:565-71.
50. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995;95:1869-76.
51. Grube E, Silber S, Hauptmann KE, Buellesfeld L, Mueller R, Lim V et al. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am J Cardiol 2005;96:79-82.
52. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-32.
53. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-95.
54. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
55. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res 2000;86:879-84.
56. Oberhoff M, Herdeg C, Al Ghobainy R, Cetin S, Kuttner A, Horch B et al. Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Catheter Cardiovasc Interv 2001;53:562-8.
57. Lovich MA, Creel C, Hong K, Hwang CW, Edelman ER. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci 2001;90:1324-35.
58. Speck U, Scheller B, Abramjuk C, Grossmann S, Mahnkopf D, Simon O. Inhibition of restenosis in stented porcine coronary arteries: uptake of Paclitaxel from angiographic contrast media. Invest Radiol 2004;39:182-6.
59. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8.
60. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8.
61. Scheller B, Speck U, Schmitt A, Clauss W, Sovak M, Bohm M et al. Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting. Invest Radiol 2002;37:29-34.
62. Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel DI, Schroder S et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000;35:1969-76.
63. Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Bohm M et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 2003;24:1462-7.
64. Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 2003;42:1415-20.
65. Clever YP, Cremers B, Krauss B, Bohm M, Speck U, Laufs U et al. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells. EuroIntervention 2011;7(Suppl K):K32-42.
66. van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 2001;47:309-18.
67. Malingre MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H et al. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer 2001;85:1472-7.
68. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
69. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24.
70. Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, Acampado E et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002;106:1195-8.
71. Margolis J, McDonald J, Heuser R, Klinke P, Waksman R, Virmani R et al. Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study. Clin Cardiol 2007;30:165-70.
72. Lovich MA, Edelman ER. Mechanisms of transmural heparin transport in the rat abdominal aorta after local vascular delivery. Circ Res 1995;77:1143-50.
73. Lovich MA, Edelman ER. Computational simulations of local vascular heparin deposition and distribution. Am J Physiol 1996;271:H2014-24.
74. Lovich MA, Edelman ER. Tissue average binding and equilibrium distribution: an example with heparin in arterial tissues. Biophys J 1996;70:1553-9.
75. Lovich MA, Brown L, Edelman ER. Drug clearance and arterial uptake after local perivascular delivery to the rat carotid artery. J Am Coll Cardiol 1997;29:1645-50.
76. Lovich MA, Philbrook M, Sawyer S, Weselcouch E, Edelman ER. Arterial heparin deposition: role of diffusion, convection, and extravascular space. Am J Physiol 1998;275:H2236-42.
77. Baumbach A, Herdeg C, Kluge M, Oberhoff M, Lerch M, Haase KK et al. Local drug delivery: impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall. Catheter Cardiovasc Interv 1999;47:102-6.
78. Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA 2004;101:9463-7.
79. Tzafriri AR, Vukmirovic N, Kolachalama VB, Astafieva I, Edelman ER. Lesion complexity determines arterial drug distribution after local drug delivery. J Control Release 2010;142:332-8.
80. Waksman R, Pakala R. Drug-eluting balloon: the comeback kid? Circ Cardiovasc Interv 2009;2:352-8.
81. Belkacemi A, Agostoni P, Voskuil M, Stella PR. Coronary bifurcation lesions treated with the drug-eluting balloon: a preliminary insight from the DEBIUT study. EuroIntervention 2011;7(Suppl K):K66-69.
82. Posa A, Hemetsberger R, Petnehazy O, Petrasi Z, Testor M, Glogar D et al. Attainment of local drug delivery with paclitaxel-eluting balloon in porcine coronary arteries. Coron Artery Dis 2008;19:243-7.
83. Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Boehm M et al. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 2006;240:411-8.
84. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004;110:810-4.
85. Cremers B, Biedermann M, Mahnkopf D, Bohm M, Scheller B. Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol 2009;98:325-30.
86. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355:2113-24.
87. Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M, Brugger A et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol 2012;59:1377-82.
88. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008;97:773-81.
89. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009;119:2986-94.
90. Mathey DG, Wendig I, Boxberger M, Bonaventura K, Kleber FX. Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention 2011;7(Suppl K):K61-65.
91. Gutierrez-Chico JL, van Geuns RJ, Koch KT, Koolen JJ, Duckers H, Regar E et al. Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first. EuroIntervention 2011;7:711-22.
92. Wohrle J, Birkemeyer R, Markovic S, Nguyen TV, Sinha A, Miljak T et al. Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. Heart 2011;97:1338-42.
93. Hehrlein C, Richardt G, Wiemer M, Schneider H, Naber C, Hoffmann E et al. Description of Pantera Lux paclitaxel-releasing balloon and preliminary quantitative coronary angiography (QCA) results at six months in patients with coronary in-stent restenosis. EuroIntervention 2011;7(Suppl K):K119-124.
94. Unverdorben M, Kleber FX, Heuer H, Figulla HR, Vallbracht C, Leschke M et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2010;99:165-74.
95. Fanggiday JC, Stella PR, Guyomi SH, Doevendans PA. Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions: the DEBIUT (drug-eluting balloon in bifurcation Utrecht) registry. Catheter Cardiovasc Interv 2008;71:629-35.
96. Kelsch B, Scheller B, Biedermann M, Clever YP, Schaffner S, Mahnkopf D et al. Dose response to Paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Invest Radiol 2011;46:255-63.
97. Albrecht T, Speck U, Baier C, Wolf KJ, Bohm M, Scheller B. Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest Radiol 2007;42:579-85.
98. Milewski K, Tellez A, Aboodi MS, Conditt GB, Yi GH, Thim T et al. Paclitaxel-iopromide coated balloon followed by "bail-out" bare metal stent in porcine iliofemoral arteries: first report on biological effects in peripheral circulation. EuroIntervention 2011;7:362-8.
99. Schmidt A, Piorkowski M, Werner M, Ulrich M, Bausback Y, Braunlich S et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol 2011;58:1105-9.
100. Herdeg C, Gohring-Frischholz K, Haase KK, Geisler T, Zurn C, Hartmann U et al. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation. Circ Cardiovasc Interv 2009;2:294-301.
101. Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol 2014;64:1568-76.
102. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008;118:1358-65.
103. Micari A, Cioppa A, Vadala G, Castriota F, Liso A, Marchese A et al. Clinical evaluation of a Paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter italian registry. JACC Cardiovasc Interv 2012;5:331-8.
104. Micari A, Cioppa A, Vadala G, Stabile E, Castriota F, Pantaleo P et al. A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: acute and midterm results. EuroIntervention 2011;7(Suppl K):K77-82.
105. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the IN.PACT SFA Randomized Trial. Circulation 2014. [Epub ahead of print]
106. LUTONIX 035 Drug Coated Balloon (DCB) PTA Catheter [FDA executive summary), 2014.
107. Herdeg C, Oberhoff M, Baumbach A, Blattner A, Kuttner A, Schroder S et al. Visualization and comparison of drug effects after local paclitaxel delivery with different catheter types. Basic Res Cardiol 1999;94:454-63.
108. Speck U, Scheller B, Rutsch W, Laule M, Stangl V. Local drug delivery - the early Berlin experience: single drug administration versus sustained release. EuroIntervention 2011;7(Suppl K):K17-22.
109. Herdeg C. Catheter based local delivery of fluid paclitaxel: the Tubingen experience. EuroIntervention 2011;7(Suppl K):K11-16.
110. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689-99.
111. Latif F, Hennebry TA. Successful revascularization of re-stenosis of lower extremity arteries with localized delivery of paclitaxel. Catheter Cardiovasc Interv 2008;72:294-8.
112. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Eng J Med 1995;332:1004-14.
113. MacDonald JE, Klinke P, Fung A, Ricci D, Suciu C, Ortan F et al. Systemic nanoparticle albumin-bound paclitaxel (nab-paclitaxel) for the prevention of in-stent restenosis (SNAPIST-II): a randomized comparison of single dose and single dose plus repeat dose at 2 months (Abstract). Cardiovasc Revasc Med 2006;7:111-2.
114. Freyhardt P, Zeller T, Kroncke TJ, Schwarzwaelder U, Schreiter NF, Stiepani H et al. Plasma levels following application of paclitaxel-coated balloon catheters in patients with stenotic or occluded femoropopliteal arteries. RoFo. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2011;183:448-55.
115. Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 2014;7:10-9.
116. Werk M, Albrecht T, Meyer DR, Ahmed MN, Behne A, Dietz U et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv 2012;5:831-40.
117. Liistro F. Drug Eluting Balloon for Below The Knee Angioplasty Evaluation: The DEBATE-BTK Study Transcatheter Cardiovascular Therapeutics. San Francisco, CA: TCTMD.com; 2011.
118. Fanelli F, Cannavale A, Boatta E, Corona M, Lucatelli P, Wlderk A et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther 2012;19:571-80.